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Abstract Combination of peginterferon and ribavirin is
the current therapy for chronic hepatitis C infection
(HCV). Interstitial pneumonitis is a rare side-effect of HCV
therapy and is an important cause of dose reduction or
discontinuation, impairing success of antiviral therapy. We
performed a review of the literature in order to present
diagnostic modalities and possible treatments for pneu-
monitis and to offer guidelines. We searched for cases
where pneumonitis as a side-effect of HCV treatment was
documented. First we performed a literature search via
PubMed and Web of Science interface and second we
searched three drug toxicity databases. We systematically
analyzed all case reports with respect to clinical manifes-
tations, type of treatment, and outcome. A literature search
revealed 19 articles, containing 25 case descriptions, while
we traced 33 cases from the drug toxicity databases.
Pneumonitis presented with any of the combination of
fever, dyspnea, and cough and can arise with any type of
(conventional or pegylated) interferon. Mortality secondary
to pneumonitis was seen in 7% of cases, exclusively with
peginterferon a-2b. In most cases therapy was discontinued
and steroids were started. Interferon-induced pneumonitis
during HCV treatment is a severe complication and should
be recognized in order to prevent further pulmonary dam-
age and/or death.
Keywords Hepatitis C  (Peg)Interferon  Ribavirin 
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Introduction
Hepatitis C (HCV) persists in up to 85% of patients and
may result in liver cirrhosis and hepatocellular carcinoma
[1]. The combination of peginterferon and ribavirin is the
mainstay of treatment. Eradication of the virus can be
achieved in up to 90% of chronic HCV patients, depending
on a number of host- and virus-related factors [1, 2].
Successful treatment results in resolution of hepatic necr-
oinﬂammation and regression of ﬁbrosis.
Though potentially successful, peginterferon and riba-
virin are known to cause various side-effects in HCV
patients. Most individuals suffer from some side-effects
such as ﬂu-like symptoms, myalgia, fatigue, gastrointesti-
nal disturbances, psychiatric disorders, and hematological
abnormalities such as anemia and leukopenia [3–5].
These adverse effects are relatively common and can be
managed with supportive care. There are also less well-
known side-effects of antiviral treatment that may hamper
successful eradication of the virus. Knowledge of the
extensive gamut of side-effects of combination therapy is
critical for the adequate management of side-effects.
Pulmonary toxicity in patients undergoing HCV combi-
nation treatment is rare, and may include interstitial pneu-
monitis, sarcoidosis, pleuritis, bronchiolitis obliterans
organizing pneumonia (BOOP), and exacerbation of asthma
[6, 7]. Pneumonitis occurs only rarely as a side-effect of
HCV combination therapy and can arise at any stage of the
treatment. Most commonly it presents with cough, which is
difﬁcult to differentiate from the ubiquitous cough that may
occurs as a common side-effect of combination treatment.
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DOI 10.1007/s10620-009-0797-1Interferon is the agent that is thought to be associated with
pneumonitis in these patients. This paper aims to review the
salient issues of pneumonitis in the setting of HCV com-
binationtreatment and aims to offer guidelines for diagnosis
and treatment of pneumonitis.
Case Description
A 51-year-old male was seen in August 2005 because of
HCV infection. He had been using intravenous (i.v.) drugs
until 1985 and his medical history revealed multiple total
hip replacements and revisions because of hip necrosis
attributed to i.v. drug-related blood-borne infections. Liver
function tests were abnormal: alanine aminotransferase
(ALAT) 237 IU/L (normal\45 IU/L), aspartate amino-
transferase (ASAT) 235 IU/L (normal\50 IU/L), c-glut-
amyl transpeptidase 241 IU/L (normal\55 IU/L), and
bilirubin 19 lmol/L (normal\10 lmol/L). The patient
was infected with genotype 3 HCV virus with high viral
load ([5 9 10
5 IU/ml). A liver biopsy was performed and
showed moderate necroinﬂammation with portoportal
ﬁbrosis (METAVIR; grade A2, score F2). In view of this
advanced stage we offered the patient a 24-week treatment
for HCV consisting of peginterferon a-2b (Pegintron
;
150 lg s.c. weekly) in combination with ribavirin (Rebe-
tol
; 400 mg twice daily).
Four weeks after starting treatment he consulted us for a
dry cough. Chest X-ray at that time showed no abnormal-
ities. Although dry, nonproductive cough is usually caused
by ribavirin, it typically clears after stopping the drug. The
dry cough, however, persisted after end of treatment, being
the reason to consult a chest physician. Physical exami-
nation revealed bibasal crepitations. A new chest radio-
graph showed bilaterally a diffuse, interstitial pattern
(Fig. 1a) and chest high-resolution computed tomography
(HRCT) demonstrated bilateral ground-glass opacities in
central and upper zones (Fig. 1b). Pulmonary function tests
indicated a restriction and a diminished diffusing capacity.
Maximal incremental cycle ergometry showed decreased
breathing reserve (0 l/min), high breathing frequency (65/
min), and exercise-induced hypoxemia caused by an oxy-
gen uptake problem, compatible with interstitial pulmonary
disease. Results from bronchoalveolar lavage supported a
diagnosis of drug-induced interstitial pneumonitis (cell
count 1.68 9 10
9/L, 73% lymphocytes, CD4/CD8 ratio
0.5). The results of cultures and stains of the bronchoal-
veolar lavage specimens were negative for bacteria, fungi,
acid-fast bacteria, cytomegalovirus, herpes simplex virus,
and malignant cells. There were no signs of infection
(blood culture was negative).
As after 6 weeks the cough persisted, steroids up to
40 mg daily were started, which resulted in slow amelio-
ration of symptoms, normalization of pulmonary function
tests, and disappearance of the ground-glass effect on
HRCT. One year after end of treatment the patient is well,
without evidence of recurrence of hepatitis C.
Methods
Literature
First we performed a literature search for articles on pneu-
monitisasaside-effectofHCVtreatmentinordertoobtaina
comprehensive overview of this particular side-effect. We
tookadvantageofthePubMed andWeb ofScienceinterface
(http://www.ncbi.nlm.entrez and http://apps.isiknowledge.
com) and searched with the following keywords: interferon,
interstitial, pneumonitis, and hepatitis C, for the period
1990–2008. Articles written in English, French or German
were included in the analysis. Furthermore, we searched the
three drug toxicity databases. We included the Netherlands
Pharmacovigilance Center (www.lareb.nl) database and the
Fig. 1 a Chest X-ray with
diffuse, bilateral interstitial
pattern. b High-resolution
computer tomography image
showing bilateral ground-glass
opacities in central zone
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com), and lastly we performed an exhaustive search of the
database of the World Health Organization (WHO) via the
Uppsala monitoring center (http://www.who-umc.org). We
used as keywords interferon and pneumonitis. The WHO
database is a collection of data about adverse drug reactions
from around the world, especially from countries that are
membersoftheWHO,andthegenerationofsignalsofdrugs
which might possibly have problematic side-effects.
Inclusion criteria were cases that developed interstitial
pneumonitis in the setting of HCV treatment, written in
English, French or German. Exclusion criteria were other
pulmonary diseases, e.g., sarcoidosis, exacerbation of
asthma, BOOP, acute respiratory distress syndrome
(ARDS), infectious pneumonia, liver transplanted patients,
HIV co-infected patients, and interferon beta treatment.
Patients who developed interstitial pneumonitis during
interferon therapy with a disease other then hepatitis C
were also excluded. The references of the traced articles
were scrutinized for additional articles.
Initial analysis yielded a total of 291 articles. The
abstracts of this set of articles were scrutinized for cases
that developed (interstitial) pneumonitis in the setting of
HCV treatment. Subsequently data were retrieved with
special attention to the following items: demographics
(ethnicity, gender, and age), dosage and type of
(peg)interferon, concomitant use of ribavirin (dosage),
symptoms, interstitial pneumonitis, onset, symptoms, and
outcome on follow-up.
Results
Articles
We retrieved 19 articles, which contained detailed clinical
descriptions of 25 cases of interstitial pneumonitis during
or after HCV treatment. Our own case was added to the
analysis. Articles were published in the time frame 1988–
2008.
Demographics and Treatment
A total of 25 cases, 12 (48%) males and 13 (52%) females,
with mean age of 55.2 years, developed an interstitial
pneumonitis. Ethnicity was mentioned in seven cases,
being Caucasian (ﬁve) and Asian (two). Tables 1 and 2
present the demographic characteristics of all cases.
Fourteen patients were treated with conventional inter-
feron, while 11 patients developed pneumonitis during or
after treatment with peginterferon and ribavirin.
Interferon Therapy Cases
Interferon a-2b had been used in eight patients (62%),
while interferon a-2a and lymphoblastoid interferon
(6 MU q.d. 9 10 days, then 6 MU t.i.w.) was used in one
single case. Interferon type was not speciﬁed in three cases.
Dosages regimes varied with type of interferon and are
presented in Table 2. Onset of symptoms of interstitial
pneumonitis ranged from 20 days to 23 weeks of therapy.
Symptoms included cough, dyspnea, and fever.
Combination Therapy Cases
Peginterferon a-2b was used in eight patients (67%), while
peginterferon a-2a was used in four patients (33%). Con-
sensus interferon (Infergen, 9 lg q.d.) was given in a single
case. Dosage regimes varied from 100 to 180 lg/week,
depending on type of peginterferon, and from 400 to
1,200 mg/day for ribavirin. In two cases Amantadine was
added to the treatment regimen.
Onset of symptoms of interstitial pneumonitis ranged
from 2 to 12 weeks of therapy.
Therapy for Interstitial Pneumonitis
In all interferon cases therapy was discontinued, and ﬁve of
these cases resolved without treatment [8–10]. Eight
patients needed to be treated with various steroids. Inter-
stitial pneumonitis in a 72-year-old female patient was
treated with 30 mg/day prednisolone, and she was then
maintained on a regimen of intermittent pulse therapy with
100 mg/day; a 56-year-old male patient was started with
2 g/day methylprednisolone for 3 days and 40 mg/day
prednisolone for 2 days [10]. Prednisolone (60 mg/day)
and 100 mg/day azathioprine were given after a relapse of
interstitial pneumonitis that was initially treated with
30 mg/day prednisolone [11].
In one case of therapy with methylprednisolone pulse
therapy, 1 g/day i.v. for 3 days was given, followed by
40 mg/day oral prednisolone twice over 2 weeks; the other
cases in that article received 50 mg/day oral prednisone
[12]. Therapy for one case was not speciﬁed [13].
In eight cases combination therapy was discontinued
and steroid therapy was initiated. While dosage and length
of steroid treatment was highly variable, most authors
started at a relatively high dosage. Intravenous therapy with
180 mg/day methylprednisolone was started in one case
[14], while other authors started with 125 mg/day pred-
nisolone [15, 16]. Others started patients on oral steroid
therapy (40 mg) [6, 17, this study], while two authors
initiated inhalation steroids [18, 19].
Interstitial lung disease resolved in one case with oral
antibiotics, given under presumptive diagnosis of
Dig Dis Sci (2010) 55:579–585 581
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123community-acquired pneumonia. She recovered without
sequel [7]. In four combination-therapy cases the dosage of
steroid therapy was not deﬁned [20–23].
Pneumonitis Cases from Drug Toxicity Databases
We identiﬁed 60 pneumonitis cases in association with
(peg)interferon a from the WHO database. In 33 cases the
indication of (peg)interferon (and ribavirin) combination
treatment was HCV. There were 16 (48%) males and 15
(45%) females in this cohort, with mean age of 53 years.
We failed to retrieve cases that met the inclusion criteria
from the Netherlands Pharmacovigilance Center and Drug-
Induced Lung Diseases databases.
Interferon monotherapy was used in three (9%) patients.
Interferon a-2b in combination with ribavirin was used in
eight patients (24%), while interferon a-2a in combination
with ribavirin was used in a single case.
Peginterferon a-2b in combination with ribavirin had
been used in 6 patients (18%), while in 13 patients (39%)
combination therapy with peginterferon a-2a was used. In
two cases type of interferon and ribavirin was not described.
Dosages regimes varied from 80 to 180 lg/week,
depending on type of peginterferon, in combination with
ribavirin (800–1,200 mg/day). Onset of symptoms of
interstitial pneumonitis ranged from 23 days to 10 months
of therapy. Four patients recovered and one patient died
after drug-induced pneumonitis; outcomes of the remaining
patients were not described. There was no description on
treatment regimen for pneumonitis.
Mortality
Collectively, the cohort consisted of 25 patients from lit-
erature cohort and 33 patients from the drug toxicity
database. Four patients (7%) from these two cohorts died
following development of interstitial pneumonitis. All
patients had been treated with peginterferon a-2b.
Death in one case was due to multiple organ failure [14],
in another case due to cerebral edema [15], and in one case
Table 2 Summary of case reports in literature of interstitial pneumonitis associated with use of pegylated interferon with ribavirin for treatment
of hepatitis C
Author and
reference
Gender Age
(years)
Ethnicity Type of
(peg)IFN
Dose (lg/
week)
Ribavirin
(mg)
Onset
(week)
Symptoms Outcome
Fuhrmann
et al. [15]
Male 51 Asian a-2b 100 1,200 5 Fever, dry
cough,
dyspnea
Death
Abi-Nassif
et al. [14]
Male 49 Caucasian a-2b 150 1,200 2 Cough and
dyspnea
Death
Carrillo-Esper
et al. [16]
Female 43   a-2b 120 800 48 Dyspnea,
cough, fever
Death
Hillier et al.
[17]
Female 68 Caucasian Consensus
IFN
9 lg daily 1,000 8 Shortness of
breath
Discontinued and steroids
Renou et al.
[18]
Female 58 Caucasian a-2b
a-2a
150
180
1,000
1,000 ? A*
12
12
Dyspnea
dyspnea
Discontinued and resolved
with inhalation steroids
Kumar et al.
[6]
Female 48 Hispanic a-2a 180   ? A* 6 Fever, cough Discontinued and resolved
with steroids
Midturi et al.
[7]
Female 71   a-2a 180 800 6 Cough,
diarrhea,
nausea
Resolved after discontinuation
Chen et al.
[20]
Female 47   a-2b      Dry cough  
Son et al. [21] Male 50   a-2a 180 1,000    Resolved after discontinuation
Rocca et al.
[22]
Male 63   a-2b   400   Signs of
pneumonia
 
Slavenburg
et al.
[this study]
Male 51 Caucasian a-2b 150 800 4 Dry cough End of treatment and resolved
with steroids
Nemivant
et al. [23]
Male 72   a-2b 150 800 16 Dyspnea,
hypoxia
Discontinuation and resolved
with steroids
Rothfuss et al.
[19]
Female 62   a-2b 4.5 MU
i.m.
t.i.w.
1,000 9 Dry cough and
dyspnea
Inhalation steroids
PEG-IFN pegylated interferon, A* Amantadine,   not speciﬁed
Dig Dis Sci (2010) 55:579–585 583
123because of development of acute cholestatic hepatitis [16].
The cause of death of one case from the WHO database
was not described.
Discussion
Interstitial pneumonitis occurs only rarely as a side-effect
of HCV combination treatment and often leads to discon-
tinuation of therapy, which has great implications for
patients. In this article we presented our case of pneumo-
nitis during combination therapy and performed a review in
order to generate guidelines to manage symptoms and
treatment. Given the paucity of reports with interstitial
pneumonitis after ribavirin monotherapy, we suspect that
interferon is the culprit.
The most common presenting symptom of pneumonitis
is any combination of dry cough, dyspnea, fever, and ﬁne
inspiratory crackles noted on examination. Hemoptysis,
wheezing, and signs of consolidation are rare. Onset of
pneumonitis can be at any stage of HCV treatment, sup-
porting the idiosyncratic nature of this side-effect.
Chest radiographs usually show bilateral patchy inﬁl-
trates or opaciﬁcations, and thin-section CT scans show
bilateral patchy consolidation as well as ground-glass
attenuation [24].
In most cases, symptoms of pneumonitis are reversible
aftercessationoftreatmentwith(peg)interferonandribavirin,
again in support of drug-induced interstitial pneumonitis.
There is no consensus regarding treatment of interstitial
pneumonitis induced by (peg)interferon and ribavirin. Upon
review of the literature, three options are possible: ﬁrst, to
stop combination treatment of HCV and wait until the dis-
ease resolves, which was done in a limited number of cases
[7–10];second,togivesteroids,althoughdosageandrouteof
administration regimes vary widely [6, 10–18, this study];
and thirdly, in therapy-resistant or relapsing cases, adding
azathioprine to steroids may be beneﬁcial in order to resolve
the interstitial pneumonitis [11].
The relatively high mortality rate in our series suggests
that a more aggressive approach is warranted, and favors
the early administration of steroids.
One remarkable ﬁnding is that mortality occurred exclu-
sivelyinpatientswithpeginterferon-inducedpneumonitisin
comparison with conventional interferon (7% versus 0%).
The reason for this is unclear, but (peg)interferon has been
associatedwithotherpulmonarytoxicitysuchassarcoidosis,
pleuritis, BOOP, and exacerbation of asthma.
Patients who died in the combination-therapy group
were relatively young and had no relevant pulmonary or
other severe diseases in their medical history. The doses of
peginterferon and ribavirin varied but ranged within limits
offered by treatment guidelines [25].
The mortality, only observed in patients treated with
peginterferon and ribavirin combination therapy, raises
the issue of whether the peg molecule increases the
severity of pneumonitis once it arises. Interferon toxicity
is generally dose and duration dependent [26], which
leads us to speculate that pulmonary toxicity may occur
more severely with long-acting peginterferon; however,
we saw no effect of dosage on the occurrence of pneu-
monitis. Patients died due to different causes (e.g.,
hypoxia-induced cerebral edema, acute cholestatic hepa-
titis, and multi-organ failure), all were induced by com-
plications after initially interstitial pneumonitis. One
alternative explanation for the increased mortality might
be that all patients with peginterferon were also treated
with ribavirin, although ribavirin per se is not associated
with pulmonary toxicity.
Our data suggest no signiﬁcant difference between
interferon a-2a or 2b, which suggest it is not due to the
interferon molecule. In most interferon monotherapy cases
of interstitial pneumonitis in HCV treatment in Japan the
use of Sho-Saiko-to, a herbal medicine, led to pneumonitis.
Sho-Saiko-to has been approved by the Japanese Ministry
of Health and Welfare and has often been administered in
chronic viral liver disease [27].
The mechanism of this side-effect, probably caused by
interferon, remains unclear and several pathophysiological
mechanisms have been proposed, centering on the known
immunomodulatory activity of interferon [28]. Interferon
has direct antiviral and immunomodulatory effect, includ-
ing cytokine reduction, increased natural killer cell func-
tion, and enhanced cellular expression of major
histocompatibility class 1 antigens [28–30]. It is plausible
that interferon triggers a lung-speciﬁc immune-mediated
response resulting in interstitial pneumonitis, similar to
other autoimmune diseases.
Conclusion
Failure to recognize interferon-associated pulmonary tox-
icity may result in persistence of pulmonary damage.
Mortality was seen only in patients treated with pegylated
interferon combination therapy. Therefore, clinicians
should be aware of development of interstitial pneumonitis
in chronic hepatitis C patients who develop pulmonary
symptoms such as cough or dyspnea. The threshold for
obtaining chest X-ray or pulmonary HRCT scan in these
patients should be low.
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